<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03253432</url>
  </required_header>
  <id_info>
    <org_study_id>826438</org_study_id>
    <nct_id>NCT03253432</nct_id>
  </id_info>
  <brief_title>IN-TANDEM Familial Hypercholesterolemia Pilot Study</brief_title>
  <official_title>INTegrating Active Case-finding With Next-generation Sequencing for Diagnosis Through Electronic Medical Records (IN-TANDEM): Familial Hypercholesterolemia Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Familial Hypercholesterolemia Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Lancaster General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to validate the use of the FH Foundation FIND FHÂ® Algorithm as a
      clinical decision support tool. FIND FH (Flag/Identify/Network/Engage) is a national
      initiative that utilizes machine learning and data mining techniques to identify individuals
      whose profiles are consistent with FH patients. The algorithm will be tested in adults with
      at least one cardiovascular comorbidity. Study subjects will be asked to provide either a
      saliva, buccal or venous blood sample for DNA and biomarker analysis
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 20, 2017</start_date>
  <completion_date type="Actual">November 7, 2018</completion_date>
  <primary_completion_date type="Actual">November 7, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Likelihood of having FH-causing mutation</measure>
    <time_frame>12 months</time_frame>
    <description>Proportion of subjects with causative mutation in higher algorithm score groups</description>
  </primary_outcome>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Actual">378</enrollment>
  <condition>Familial Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>Strata 0-0.05</arm_group_label>
    <description>Lowest probability of having familial hypercholesterolemia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Strata 0.06-0.15</arm_group_label>
    <description>Second lowest probability of having familial hypercholesterolemia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Strata 0.16-0.19</arm_group_label>
    <description>Moderate probability of having familial hypercholesterolemia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Strata 0.20-0.34</arm_group_label>
    <description>Second highest probability of having familial hypercholesterolemia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Strata greater than or equal to 35</arm_group_label>
    <description>Highest probability of having familial hypercholesterolemia</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Genetic testing</intervention_name>
    <description>Targeted next-generation sequencing for familial hypercholesterolemia causative mutations</description>
    <arm_group_label>Strata 0-0.05</arm_group_label>
    <arm_group_label>Strata 0.06-0.15</arm_group_label>
    <arm_group_label>Strata 0.16-0.19</arm_group_label>
    <arm_group_label>Strata 0.20-0.34</arm_group_label>
    <arm_group_label>Strata greater than or equal to 35</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Randomly selected patients from University of Pennsylvania and Lancaster General Hospital
        with at least 1 cardiovascular comorbidity seen at hospital within the past five years.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 years or older

          -  At least one cardiovascular co-morbidity or receiving treatment for a cardiovascular
             comorbidity

          -  Algorithm score 0-1

          -  Most recent encounter with a provider within five years of query date

        Exclusion Criteria:

          -  Any medical or psychological conditions that, in the opinion of the investigator,
             would compromise the subject's safety or successful participation in the study, or
             confound study data
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Lancaster General Hospital</name>
      <address>
        <city>Lancaster</city>
        <state>Pennsylvania</state>
        <zip>17602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>August 15, 2017</study_first_submitted>
  <study_first_submitted_qc>August 15, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 17, 2017</study_first_posted>
  <last_update_submitted>February 27, 2019</last_update_submitted>
  <last_update_submitted_qc>February 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperlipoproteinemia Type II</mesh_term>
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified data will be shared with other investigators</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>De-identified data will be shared at end of study after database lock</ipd_time_frame>
    <ipd_access_criteria>Research team</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

